Alzheimer's Disease Diagnostic Market Growth Forecast At 8.90% CAGR To Hit 8.8 Billion USD By 2032
Alzheimer's disease Diagnostic market Insights: Rising prevalence of Alzheimer's and focus on early diagnosis drive growth.
PsyPost on MSN3d
Focused ultrasound shows promise in treating Alzheimer’s by reducing amyloid plaques
A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...
Costly Therapies To Foster Alzheimer’S Market Growth Globally: Report
The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...
Hosted on MSN5d
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial
The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...
Alzheimer’s total prevalent cases to reach 22.51 million in 8MM in 2033
GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...
MedPage Today8d
For Your Patients: What to Expect With Early Stage Alzheimer’s Disease
"During the early stage, it's possible for people with dementia to live well by taking control of their health and wellness, ...
Taiwan News8d
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...
clinicaltrialsarena9d
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...
technologynetworks10d
Head Trauma Reactivates Hidden Viruses That Fuel Alzheimer’s Disease
A study led by Tufts University and Oxford University has revealed that head trauma can reactivate dormant herpes simplex ...
Healio10d
Alzheimer’s experts revise guidelines for amyloid, tau PET utilization
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...